CN102088993A - 炎症的治疗方法 - Google Patents

炎症的治疗方法 Download PDF

Info

Publication number
CN102088993A
CN102088993A CN2009801093284A CN200980109328A CN102088993A CN 102088993 A CN102088993 A CN 102088993A CN 2009801093284 A CN2009801093284 A CN 2009801093284A CN 200980109328 A CN200980109328 A CN 200980109328A CN 102088993 A CN102088993 A CN 102088993A
Authority
CN
China
Prior art keywords
mif
peptide
certain embodiments
cxcr2
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801093284A
Other languages
English (en)
Chinese (zh)
Inventor
于尔根·伯恩哈根
乔舒亚·罗伯特·舒尔茨
贝内迪克特·福尔拉特
阿尔玛·策内克
克里斯蒂安·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of CN102088993A publication Critical patent/CN102088993A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
CN2009801093284A 2008-03-20 2009-03-20 炎症的治疗方法 Pending CN102088993A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3838108P 2008-03-20 2008-03-20
US61/038,381 2008-03-20
US3937108P 2008-03-25 2008-03-25
US61/039,371 2008-03-25
US4580708P 2008-04-17 2008-04-17
US61/045,807 2008-04-17
US12109508P 2008-12-09 2008-12-09
US61/121,095 2008-12-09
PCT/US2009/037887 WO2009117710A2 (en) 2008-03-20 2009-03-20 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
CN102088993A true CN102088993A (zh) 2011-06-08

Family

ID=41091567

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801093284A Pending CN102088993A (zh) 2008-03-20 2009-03-20 炎症的治疗方法
CN200980109905XA Pending CN102046199A (zh) 2008-03-20 2009-03-20 使用抗mif抗体的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980109905XA Pending CN102046199A (zh) 2008-03-20 2009-03-20 使用抗mif抗体的治疗方法

Country Status (14)

Country Link
US (2) US20110044988A1 (https=)
EP (2) EP2252318A4 (https=)
JP (2) JP2011526244A (https=)
KR (1) KR20110014141A (https=)
CN (2) CN102088993A (https=)
AU (2) AU2009225389A1 (https=)
BR (1) BRPI0910259A2 (https=)
CA (2) CA2717071A1 (https=)
CO (1) CO6300848A2 (https=)
EA (1) EA201001529A1 (https=)
IL (1) IL207752A0 (https=)
MX (1) MX2010010198A (https=)
NZ (1) NZ588033A (https=)
WO (2) WO2009117710A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427574A (zh) * 2015-01-09 2017-12-01 阿达尔塔私人有限公司 Cxcr4结合分子
WO2018137701A1 (zh) * 2017-01-26 2018-08-02 中国医学科学院阜外医院 靶向cxcr7的药物组合物和方法
CN108368485A (zh) * 2015-09-18 2018-08-03 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的天然杀伤细胞及其用途
CN109069426A (zh) * 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
AU2010298249A1 (en) * 2009-09-23 2012-04-19 Carolus Therapeutics, Inc. Methods of treating inflammation
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US9133164B2 (en) * 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
TWI407964B (zh) * 2011-05-10 2013-09-11 Univ Fu Jen Catholic 干擾性核糖核酸用於治療或減緩疼痛之用途
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US10596233B2 (en) 2011-06-30 2020-03-24 Dignity Health Use of pertussis toxin as a therapeutic agent
US9801921B2 (en) 2011-06-30 2017-10-31 Dignity Health Use of pertussis toxin as a therapeutic agent
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
CN102357249A (zh) * 2011-10-26 2012-02-22 广州赫尔氏药物开发有限公司 能够抑制耐药性结核杆菌的药物
ES2656292T3 (es) 2012-05-01 2018-02-26 Translatum Medicus Inc. Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
WO2015051330A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
KR102645432B1 (ko) * 2016-03-28 2024-03-11 (주)아모레퍼시픽 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3445402A4 (en) * 2016-04-21 2019-12-11 The Board Of Regents Of The University Of Texas System METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
US11291641B2 (en) * 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
US11767564B2 (en) * 2017-10-27 2023-09-26 Board Of Regents, The University Of Texas System Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma
CN107964045B (zh) * 2017-12-18 2021-04-23 南京医科大学 一种人鼠嵌合抗CXCR2全分子IgG及其应用
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110133306B (zh) * 2019-05-09 2023-04-07 北京勤邦生物技术有限公司 检测西马特罗的酶联免疫试剂盒及其应用
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CA3174634A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
EP4237002A4 (en) * 2020-10-28 2025-02-12 University Health Network METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF
WO2022203308A1 (ko) * 2021-03-22 2022-09-29 클립스비엔씨 주식회사 신규한 재조합 마이코박테리움 스메그마티스 균주 및 이의 용도
JP2024516548A (ja) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法
KR102561554B1 (ko) * 2021-04-14 2023-07-28 부산대학교 산학협력단 치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트
WO2023150294A2 (en) * 2022-02-04 2023-08-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of detecting and treating cerebral aneurysms
WO2025171411A1 (en) * 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
CN121714692A (zh) * 2026-02-26 2026-03-24 华中科技大学同济医学院附属协和医院 Cxcl14抑制剂在制备用于预防或治疗患者腹主动脉瘤的药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435303D1 (de) * 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
BR0206986A (pt) * 2001-01-12 2005-11-01 Cytokine Pharmasciences Inc Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago
JP2003226653A (ja) * 2001-11-30 2003-08-12 Jun Nishihira 多発性硬化症治療剤
WO2003047622A1 (fr) * 2001-11-30 2003-06-12 Jun Nishihira Remedes pour la sclerose en plaques
US6656168B2 (en) * 2001-12-18 2003-12-02 Kimberly-Clark Worldwide, Inc. Feminine care product with discrete areas of a skin wellness additive
WO2003072753A2 (en) * 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
WO2004049095A2 (en) * 2002-11-25 2004-06-10 Jallal Messadek Betaine and salicylic acid compositions
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US20060257466A1 (en) * 2005-04-06 2006-11-16 Kim Perry M Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JPWO2007138961A1 (ja) * 2006-05-29 2009-10-08 レドックス・バイオサイエンス株式会社 マクロファージ遊走阻止因子阻害剤
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
US20110256130A1 (en) * 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427574A (zh) * 2015-01-09 2017-12-01 阿达尔塔私人有限公司 Cxcr4结合分子
CN114478773A (zh) * 2015-01-09 2022-05-13 阿达尔塔有限公司 Cxcr4结合分子
CN108368485A (zh) * 2015-09-18 2018-08-03 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的天然杀伤细胞及其用途
CN109069426A (zh) * 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2018137701A1 (zh) * 2017-01-26 2018-08-02 中国医学科学院阜外医院 靶向cxcr7的药物组合物和方法
CN110225768A (zh) * 2017-01-26 2019-09-10 中国医学科学院阜外医院 靶向cxcr7的药物组合物和方法
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物
CN113383235B (zh) * 2018-12-26 2024-07-26 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物

Also Published As

Publication number Publication date
WO2009117710A2 (en) 2009-09-24
CO6300848A2 (es) 2011-07-21
MX2010010198A (es) 2010-12-21
JP2011526244A (ja) 2011-10-06
IL207752A0 (en) 2010-12-30
WO2009117710A3 (en) 2010-01-21
WO2009117706A2 (en) 2009-09-24
CA2717071A1 (en) 2009-09-24
NZ588033A (en) 2012-11-30
EP2252318A4 (en) 2012-04-18
EP2252318A2 (en) 2010-11-24
CN102046199A (zh) 2011-05-04
US20110044988A1 (en) 2011-02-24
US20110262386A1 (en) 2011-10-27
CA2717365A1 (en) 2009-09-24
EA201001529A1 (ru) 2011-06-30
EP2254597A2 (en) 2010-12-01
BRPI0910259A2 (pt) 2015-12-01
JP2011515416A (ja) 2011-05-19
AU2009225389A1 (en) 2009-09-24
KR20110014141A (ko) 2011-02-10
WO2009117706A3 (en) 2010-01-21
AU2009225385A1 (en) 2009-09-24
EP2254597A4 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
CN102088993A (zh) 炎症的治疗方法
CN114245807B (zh) Flt3l-fc融合蛋白和使用方法
CN102725311A (zh) 治疗发炎的方法
US8133857B2 (en) NOTCH inhibition in the treatment of atherosclerosis
DE60317677T2 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP2906241B1 (en) Enhancement of the immune response
CN101720232B (zh) 具有修饰的效应器功能的fc受体结合型多肽
US20190284295A1 (en) Antibodies That Bind CD39 and Uses Thereof
KR20110074898A (ko) 염증을 치료하는 방법
ES2588484T3 (es) Anticuerpo anti-ADAMTS-5, derivados y usos del mismo
US20230203166A1 (en) B7h3-targeting proteins and methods of use thereof
CA2716628A1 (en) Methods and compositions for treating atherosclerosis and related conditions
US20240199732A1 (en) Anti-IL-27 Antibodies and Uses Thereof
US20230181750A1 (en) Mask peptides and masked anti-ptk7 antibodies comprising such
KR20250067121A (ko) Cnx 항원-결합 분자
JP4931347B2 (ja) 抗−ｔｓｇ１０１抗体およびウイルス感染の処置に対するそれらの用法
JP2022511437A (ja) Ｈｉｖ感染の組み合わせ治療
WO2025007057A2 (en) Lymphocyte trafficking receptor and ligand
EA052811B1 (ru) Антитела против ил-27 и их применение
HK40126807A (zh) Cnx抗原结合分子
BR112022006760B1 (pt) Anticorpo anti-receptor semelhante a quemerina 1 ou fragmentos de ligação ao antígeno do mesmo e usos preventivos ou terapêuticos do mesmo
HK40042823A (en) Anti-cd73 antibodies and methods of use thereof
BR112020025721A2 (pt) Anticorpos que visam a gp120 do hiv e métodos de uso
HK1213791B (en) Enhancement of the immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110608